A 68-year-old woman with chronic obstructive pulmonary disease (COPD) GOLD stage 2 and essential hypertension presents to the outpatient clinic. Her blood pressure is 156/94 mmHg and she reports no dyspnea at rest. Her FEV₁ is 65% predicted. She has been on inhaled salbutamol and tiotropium for COPD management. The physician decides to initiate antihypertensive therapy. Which of the following beta-blockers would be the SAFEST choice in this patient?

Explanation

## Clinical Dilemma: Beta-Blockers in COPD Beta-blockers are generally contraindicated in COPD because non-selective agents block β₂-receptors on bronchial smooth muscle, causing bronchoconstriction. However, highly cardioselective agents can be used cautiously in mild-to-moderate COPD. ## Why Bisoprolol Is the Safest Choice **Key Point:** Bisoprolol is the MOST cardioselective beta-blocker available at therapeutic doses (β₁:β₂ selectivity ratio >100:1). At doses ≤10 mg/day, it has negligible effects on β₂-receptors and causes minimal airway obstruction. **High-Yield:** Among all beta-blockers, bisoprolol and nebivolol offer the highest β₁-selectivity. Bisoprolol is preferred over metoprolol in COPD because: 1. **Superior cardioselectivity** — maintains β₂-receptor function in airways 2. **Minimal airway resistance increase** — studies show <5% increase in FEV₁ decline 3. **Suitable for mild-to-moderate COPD** — this patient's FEV₁ of 65% is acceptable 4. **Long half-life** — allows once-daily dosing, improving adherence **Clinical Pearl:** The degree of cardioselectivity is dose-dependent. At high doses, even "selective" agents lose selectivity and block β₂-receptors. Bisoprolol maintains selectivity even at higher doses better than metoprolol. ## Beta-Blocker Selectivity Hierarchy | Rank | Agent | β₁:β₂ Selectivity Ratio | Safety in COPD | | --- | --- | --- | --- | | 1 | Bisoprolol | >100:1 | **Safe** (mild-moderate COPD) | | 2 | Nebivolol | ~100:1 | **Safe** (mild-moderate COPD) | | 3 | Metoprolol | ~30:1 | Caution (COPD) | | 4 | Atenolol | ~50:1 | Caution (COPD) | | 5 | Labetalol | ~7:1 (non-selective) | **Avoid** (COPD) | | 6 | Propranolol | 1:1 (non-selective) | **Contraindicated** (COPD) | **Mnemonic:** **"BAN the CLAP"** — **B**isoprolol, **A**tenolol, **N**ebivolol are acceptable; **C**arvedilol, **L**abetalol, **A**cetbutolol, **P**ropranolol are avoided in COPD. ## Why Other Options Are Less Ideal - **Metoprolol succinate (Option A):** While cardioselective, it has lower selectivity than bisoprolol (~30:1 vs >100:1) and greater risk of airway obstruction. Mortality benefit applies to heart failure, not hypertension alone. - **Labetalol (Option C):** Non-selective with significant β₂-blockade; can cause bronchoconstriction. Not suitable for COPD patients. - **Carvedilol (Option D):** Non-selective with α-blockade; causes bronchoconstriction and is contraindicated in COPD despite antioxidant properties. [cite:KD Tripathi 8e Ch 12]